Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Message Pharmaceuticals, Inc.
0 Patents (Medical) associated with Message Pharmaceuticals, Inc.
01 Aug 2003·Current opinion in investigational drugs (London, England : 2000)
Bacterial RNase P as a potential target for novel anti-infectives.
Review
Author: Eder, Paul S ; Vioque, Agustin ; Hatfield, Cynthia ; Gopalan, Venkat
The diversity of higher-order structure in ribonucleoprotein (RNP) complexes makes them amenable to small-molecule modulation of their biological function. This review will discuss why bacterial RNase P, a simple yet essential ubiquitous and highly conserved RNP enzyme, represents an excellent target for the discovery and development of novel antimicrobials.
Post-transcriptional regulation of TNFα secretion: Identification of a novel series of mRNA binding TNFα inhibitors
Author: Powers, Gordon D. ; Conway, Samuel C. ; Sturgess, Michael A. ; Waggoner, Shelly A. ; Woods, Michael P. ; Green, Alicia ; Giordano, Tony ; Temeles, Gretchen L.
In vitro and in vivo studies have unambiguously demonstrated that the induction of Tumor Necrosis Factor α(TNFα) secretion in response to extracellular stimuli such as LPS is a combination of transcriptional up-regulation of TNFα mRNA and post-transcriptional up-regulation of TNFα polypeptide.The post-transcriptional component of this induction has been shown to be regulated by an AU-rich element within the 3′-UTR of TNFα mRNA.A high throughput screening effort focused on this AU-rich element has identified a series of unique guanylhydrazone compounds that were subsequently shown to inhibit TNFα secretion in a range of assay formats.The mechanism of action of a representative example of these initial guanylhydrazones has been examinedInitial SAR studies have examined both the flexibility and shape of these compounds, leading to a series of second-generation guanylhydrazones displaying both reduced size and charge.
Current opinion in investigational drugs
Bacterial RNase P as a potential target for novel anti-infectives.
Author: Gopalan ; Hatfield C ; Vioque A ; Eder Ps
The diversity of higher-order structure in ribonucleoprotein (RNP) complexes makes them amenable to small-molecule modulation of their biological function. This review will discuss why bacterial RNase P, a simple yet essential ubiquitous and highly conserved RNP enzyme, represents an excellent target for the discovery and development of novel antimicrobials.
100 Deals associated with Message Pharmaceuticals, Inc.
100 Translational Medicine associated with Message Pharmaceuticals, Inc.